Bellevue Group AG

Q3 2024 13F-HR Detailed Holdings

Location
Kuesnacht, V8
Holdings as of
9/30/2024
Date filed
11/14/2024
Form type
13F-HR
Num holdings
196
Total value ($000)
$6,172,628
Net value change ($000)
+18,299 (0.3%)
New positions
11
Sold out positions
15
Turnover %
0.9%
Sector allocation + QoQ delta (equities-only)

Holdings broken out by other managers reported in the original SEC filing. View aggregated holdings

Prev filing: 8/14/2024 Next filing: 2/14/2025 SEC filing
You are on the SEC detailed breakdown page. Rows are shown as reported in the filing (including other manager, discretion, and voting authority fields), and are not merged like the standard holdings view. Switch to aggregated holdings.

Snapshot: Change Analysis

Compared to Q2 2024
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
EXAS 49,775 101.7%
ARGX 45,511 15.3%
EVH 43,582 136.5%
CDNA 37,455 61.6%
ABT 31,931 19.1%
BHVN 31,143 44.0%
UNH 27,133 25.9%
RVMD 25,737 13.2%
INSP 24,480 146.7%
BMRN 18,964 441.0%
Top Reduces (Value $000, Stocks/ETFs)
MRNA -78,710 -42.4%
IONS -78,244 -19.9%
DXCM -75,662 -52.6%
NBIX -46,639 -17.8%
EW -41,591 -35.7%
CRL -33,671 -70.0%
INSM -30,097 -44.0%
BIO -26,962 -63.6%
Silk Road Medical Inc -23,127 -100.0%
CNC -21,416 -76.6%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 219 (0.0% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type Discretion Other Manager Sole Shared None

Other Managers

Num Name File Number
1 BB Biotech AG 28-06964
2 Bellevue Asset Management AG 28-16892
3 Bellevue Asset Management (UK) Ltd. 28-20408